title: Novel therapeutic agents in the treatment of metastatic colorectal cancer.
abstract: Over the past couple of decades considerable progress has been made in the management of metastatic colorectal cancers (mCRC) leading to a significant improvement in five-year survival. Although part of this success has been rightly attributed to aggressive surgical management and advances in other adjunct treatments, our understanding of the pathogenesis of cancer and emergence of newer molecular targets for colon cancer has created a powerful impact. In this review article we will discuss various targeted therapies in the management of mCRC. Newer agents on the horizon soon to be incorporated in clinical practice will be briefly reviewed as well.
authors.affiliation: Sachin Gopalkrishna Pai, Northwestern Medicine Developmental Therapeutics Institute, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL 60611, United States.
authors.forename: Sachin Gopalkrishna
authors.initials: SG
authors.lastname: Pai
authors.affiliation: Sachin Gopalkrishna Pai, Northwestern Medicine Developmental Therapeutics Institute, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL 60611, United States.
authors.forename: Jyotsna
authors.initials: J
authors.lastname: Fuloria
keywords: Anti-angiogenesis inhibitors; Epidermal growth factor receptor inhibitors; Metastatic colorectal cancer; Molecular targeted drugs; Novel therapeutic agents